Infigratinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Infigratinib
Accession Number
DB11886
Type
Small Molecule
Groups
Investigational
Description

Infigratinib is under investigation for the treatment of Head and Neck Squamous Cell Carcinoma.

Structure
Thumb
Synonyms
Not Available
External IDs
BGJ-398 / BGJ398
Product Ingredients
IngredientUNIICASInChI Key
Infigratinib Acetate03D0789NYP1310746-17-8XHCQHOGMMJKLRU-UHFFFAOYSA-N
Infigratinib HydrochlorideWY8VD4RV771310746-15-6VBAIJSJSFCXDJB-UHFFFAOYSA-N
Infigratinib MesylateE223Z0KWCC1310746-12-3BXJJFNXYWJLBOS-UHFFFAOYSA-N
Infigratinib Phosphate58BH47BV6S1310746-10-1GUQNHCGYHLSITB-UHFFFAOYSA-N
Categories
UNII
A4055ME1VK
CAS number
872511-34-7
Weight
Average: 560.475
Monoisotopic: 559.186543307
Chemical Formula
C26H31Cl2N7O3
InChI Key
QADPYRIHXKWUSV-UHFFFAOYSA-N
InChI
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
IUPAC Name
N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-N-methylcarbamimidic acid
SMILES
CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(O)=NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Infigratinib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Infigratinib.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Infigratinib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Infigratinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Infigratinib.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Infigratinib.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Infigratinib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Infigratinib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Infigratinib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Infigratinib.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Infigratinib.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Infigratinib.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Infigratinib.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Infigratinib.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Infigratinib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Infigratinib.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Infigratinib.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Infigratinib.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Infigratinib.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
53235510
PubChem Substance
347828222
ChemSpider
26333103
BindingDB
50355393
ChEBI
63451
ChEMBL
CHEMBL1852688
HET
07J
PDB Entries
3tt0

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 / Advanced Solid Tumors With Alterations of FGFR1, 2 and/or 3 / Advanced Solid Tumors With FGFR1 Amplication / Advanced Solid Tumors With FGFR2 Amplication / Advanced Solid Tumors With FGFR3 Mutation / Bladder Cancer With FGFR3 Mutation or Fusion / Squamous Lung Cancer With FGFR1 Amplification1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Solid Tumors1
1RecruitingTreatmentTumor With Alterations of the FGF-R1
1WithdrawnTreatmentCancer of Cervix / Tumors1
1, 2Active Not RecruitingTreatmentAdvanced Gastrointestinal Stromal Tumor (GIST)1
1, 2WithdrawnTreatmentAdenocarcinoma of the Pancreas / Colon Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Rectal Adenocarcinoma / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2Active Not RecruitingTreatmentMelanoma1
2Active Not RecruitingTreatmentRecurrent Glioblastoma or Other Glioma Subtypes1
2Not Yet RecruitingTreatmentFGFR Gene Amplification / FGFR1 Gene Amplification / FGFR2 Gene Amplification / FGFR2 Gene Mutation / FGFR3 Gene Mutation / Head and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Infections / Recurrent Head and Neck Carcinoma / Recurrent Nasopharynx Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma1
2RecruitingTreatmentAdvanced Cholangiocarcinoma1
2RecruitingTreatmentMalignancies, Hematologic / Tumors, Solid1
Not AvailableRecruitingTreatmentBladder Cancers / Non-Muscle-Invasive Urothelial Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0183 mg/mLALOGPS
logP4.9ALOGPS
logP4.56ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)7.2ChemAxon
pKa (Strongest Basic)8.28ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.58 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity154.58 m3·mol-1ChemAxon
Polarizability58.63 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Dimethoxybenzenes / N-phenylureas / Methoxyanilines / Dialkylarylamines / Dichlorobenzenes / Phenoxy compounds / Anisoles / Alkyl aryl ethers / N-alkylpiperazines
show 13 more
Substituents
N-arylpiperazine / Phenylpiperazine / Dimethoxybenzene / M-dimethoxybenzene / N-phenylurea / Methoxyaniline / 1,3-dichlorobenzene / Phenol ether / Methoxybenzene / Tertiary aliphatic/aromatic amine
show 35 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
N-arylpiperazine, ureas, aminopyrimidine, dichlorobenzene, N-alkylpiperazine (CHEBI:63451)

Drug created on October 20, 2016 14:57 / Updated on November 09, 2017 04:58